Please watch this webcast. Again, 75% of all HER2+ patients will also be VEGF+ and dramatic results have been seen with herceptin + avastin mono-therapy; that is, without chemotherapy.
For a direct link to the lecture:
http://65.110.82.117/sabcs/player/mm1_01.html
Thank you Joe for the update,
Al